View highlights and coverage from leading international Endocrinology congresses
TouchENDOCRINOLOGY joins Prof Luca Valenti (University of Milan, Italy) at the Digital NAFLD Summit 2021 to discuss his hopes for the conference and the most exciting new developments in the field of non-alcoholic fatty liver disease (NAFLD). Questions Could you give us an overview of the clinical spectrum of non-alcoholic fatty liver disease (NAFLD) and […]
We continue our discussion with Prof. Rohit Loomba (University of California, San Diego, CA, USA) by exploring the results for the phase 2 study investigating pemafibrate in NAFLD. Part 1 of our video interview can be found here. His presentation entitled ‘Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARM alpha), improves liver stiffness […]
It was a pleasure to speak with Prof. Rohit Loomba (University of California, San Diego, CA, USA) about the rationale for the use of the novel SPPARM inhibitor, pemafibrate, in the treatment of NAFLD. Part 2 of our discussion can be found here. His presentation entitled ‘Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator […]
It was a pleasure to meet with IDF President, Prof. Andrew Boulton (University of Manchester, UK) ahead of this year’s virtual meeting to discuss anticipated congress highlights and the relationship between COVID-19 and diabetes. Questions What do you expect to be the highlights of this year’s IDF Congress? (0:20) What have we learned about the […]
Prof. Dr Sven Francque (University of Antwerp, Belgium) kindly spoke with us about the additional analysis of the phase 2b NATIVE trial investigating lanifibranor in patients with NASH. His presentation entitled ‘Lanifibranor therapy improves markers of lipid metabolism, insulin resistance, liver injury and fibrosis in patients with NASH and F2 and F3 fibrosis stages: a […]
It was a pleasure to speak with Prof. Dr Sven Francque (University of Antwerp, Belgium) about the recent post-hoc analysis of the phase 2 trial of semaglutide in patients with NASH. The analysis was designed to assess whether patient and disease characteristics influenced the effect of the drug on the resolution of NASH. His abstract […]
It was an absolute pleasure to speak with Dr Kenneth Cusi (University of Florida, Gainesville, FL, USA) about the novel compound PXL770 and the results of the STAMP-NAFLD phase 2 trial investigating its potential in NASH. His abstract entitled ‘Human proof-of-concept in non-alcoholic liver disease (NAFLD) patients with PXL770, a novel first-in-class direct AMP-kinase activator […]
In Part 2, we speak with Prof. Arun Sanyal (Virginia Commonwealth University, Richmond, VA, USA) about the interim analysis from the ICONA trial (NCT04052516) which is designed to investigate icosabutate as a potential therapeutic approach to address liver- and cardiovascular-related morbidity and mortality in patients with NASH. His abstract entitled ‘Icosabutate, a novel structurally engineered […]
In Part 1, Prof. Arun Sanyal (Virginia Commonwealth University, Richmond, VA, USA) speaks to us about the mechanism of action of icosabutate, a novel engineered fatty acid currently under investigation in NASH. He continues this conversation in Part 2 where we discuss the results from the interim analysis of the ICONA trial (NCT04052516). His abstract […]
Get the latest clinical insights from touchENDOCRINOLOGY
